Skip to main content
. 2024 Jun 26;385:e078483. doi: 10.1136/bmj-2023-078483

Fig 2.

Fig 2

Cumulative incidence curves for SGLT-2 inhibitors versus DPP-4 inhibitors (upper panel), GLP-1 receptor agonists versus DPP-4 inhibitors (middle panel), and SGLT-2 inhibitors versus GLP-1 receptor agonists (lower panel) for primary outcome of risk of hyperkalemia diagnosis in inpatient or outpatient setting after 1:1 propensity score matching. DPP-4=dipeptidyl peptidase-4; GLP-1=glucagon-like peptide-1; SGLT-2=sodium-glucose cotransporter-2